Overview
Proliferative fasciitis (PF) is a rare benign fibroblastic proliferation characterized by the presence of myofibroblasts and ganglion-like cells, often mistaken for more aggressive neoplasms due to its histological complexity. It typically affects young to middle-aged adults, with a predilection for the upper extremities and head and neck regions, though intradermal variants can occur less commonly in these areas. Clinically significant due to its pseudosarcomatous appearance, accurate diagnosis is crucial to avoid unnecessary aggressive treatments. Understanding PF is vital in day-to-day practice to ensure appropriate management and patient reassurance, avoiding undue anxiety and overtreatment 1.Pathophysiology
The exact pathophysiology of proliferative fasciitis remains incompletely understood, but it is generally considered a reactive process rather than a neoplastic one. The condition likely arises from localized trauma or chronic irritation, triggering an exaggerated fibroblastic response. Histologically, PF features a proliferation of myofibroblasts and large polygonal cells with abundant cytoplasm, indicative of an intense reparative or reactive mechanism. Molecular studies have occasionally identified genetic alterations, such as MYH9 gene rearrangements, suggesting a potential neoplastic origin in some cases, though these findings are not universal 1. The interplay between mechanical stress, inflammatory mediators, and cellular proliferation contributes to the characteristic lesion formation, highlighting the importance of both mechanical and biological factors in its development 1.Epidemiology
Proliferative fasciitis is exceedingly rare, with most reported cases being subcutaneous lesions predominantly affecting middle-aged individuals with no significant sex predilection. The intradermal variant is even rarer, with only a handful of documented cases, primarily localized to the head and neck region. Specific incidence and prevalence figures are not widely reported due to the rarity of the condition. Risk factors include a history of trauma or chronic irritation at the site of lesion development, though broader demographic trends or geographic predispositions have not been extensively delineated 1.Clinical Presentation
Proliferative fasciitis typically presents as a rapidly growing, firm, often tender nodule, usually measuring 1–7 cm in diameter. Patients commonly report intermittent pain, particularly if the lesion is subjected to pressure or trauma. The lesion may exhibit episodes of swelling and pain exacerbation, especially in cases associated with underlying conditions like chondrodermatitis nodularis helicis. Intradermal variants may present with similar features but are less frequently encountered and more localized to the head and neck region. Red-flag features include rapid growth, significant pain disproportionate to physical examination findings, and associated systemic symptoms, which warrant urgent evaluation to exclude more aggressive pathologies 1.Diagnosis
Diagnosis of proliferative fasciitis involves a combination of clinical assessment and histopathological examination. Clinically, the presence of a solitary, tender nodule with a history of trauma or chronic irritation should raise suspicion. Definitive diagnosis relies on biopsy and histopathological analysis, where characteristic features include:Histopathological Criteria:
- Proliferation of large polygonal cells with abundant amphophilic cytoplasm and prominent nuclei.
- Presence of myofibroblasts arranged in short intersecting fascicles within a fibromyxoid stroma.
- Absence of significant cytologic atypia or mitotic activity.
- Positive staining for smooth muscle actin (SMA) and negative for markers of malignancy such as AE1/AE3, p63, and Melan-A.
- Fluorescence in situ hybridization (FISH) typically negative for MYH9 gene rearrangement, though exceptions exist 1.Differential Diagnosis:
- Reticulohistiocytoma: Distinguished by positive staining for macrophage markers (CD68, CD163) and S100 protein.
- Cutaneous Monocytic Leukemia: Typically presents with multiple lesions and systemic symptoms, with positive markers of monocytic lineage.
- Epithelioid Fibrous Histiocytoma: Smaller epithelioid cells, often with an epidermal collarette, and positive for S100 protein.
- Intradermal Spitz Nevus: Smaller, more uniform cells with a characteristic dendritic morphology.
- Pleomorphic Dermal Sarcoma/Atypical Fibroxanthoma: Shows significant nuclear atypia and mitotic activity, distinguishing it from PF 1.Management
Initial Management
Surgical Excision: Complete surgical excision with clear margins is the primary treatment modality.
- Specifics: Wide local excision to ensure complete removal of the lesion.
- Monitoring: Regular follow-up to assess for recurrence and ensure wound healing.Secondary Management
Observation: For benign lesions with complete excision, close clinical follow-up is sufficient.
- Intervals: Follow-up visits every 3-6 months for the first year, then annually.
- Monitoring: Clinical examination and imaging if recurrence is suspected.Refractory or Recurrent Cases
Referral to Specialist: Consider referral to a dermatopathologist or orthopedic surgeon if there is diagnostic uncertainty or recurrence.
- Evaluation: Detailed histopathological review and possibly additional imaging studies.
- Management: Further surgical intervention or multidisciplinary approach may be necessary.Complications
Recurrent Lesions: Potential for recurrence if excision margins are not adequately clear.
- Management Triggers: Persistent symptoms or clinical signs of recurrence warrant prompt re-evaluation.
Malignant Transformation: Although rare, atypical features on histology necessitate close monitoring and possible referral to oncology.
- Indicators: Presence of significant nuclear atypia, mitotic activity, or positive FISH for MYH9 rearrangement.Prognosis & Follow-up
The prognosis for proliferative fasciitis is generally excellent with complete surgical excision. Recurrence is uncommon when adequate margins are achieved. Prognostic indicators include the completeness of surgical resection and absence of atypical histological features. Recommended follow-up intervals include:
Initial Follow-up: Within 2-4 weeks post-surgery to assess healing.
Subsequent Visits: Every 3-6 months for the first year, then annually to monitor for recurrence or complications.
Monitoring: Clinical examination, with imaging if clinically indicated 1.Special Populations
Pediatrics: While rare, PF can occur in children; diagnosis and management follow similar principles as in adults, with emphasis on thorough histopathological evaluation.
Elderly: Older patients may present with atypical features due to comorbid conditions; careful clinical assessment and biopsy are crucial.
Comorbid Conditions: Patients with chronic skin conditions or underlying inflammatory disorders may have increased risk due to persistent irritation; management should address underlying factors 1.Key Recommendations
Suspect Proliferative Fasciitis in Young to Middle-aged Adults with Rapidly Growing, Tender Nodules: Especially in regions prone to trauma or chronic irritation (Evidence: Moderate) 1.
Perform Histopathological Examination for Definitive Diagnosis: Characterized by myofibroblasts and large polygonal cells with negative markers for malignancy (Evidence: Strong) 1.
Ensure Complete Surgical Excision with Clear Margins: Primary treatment to prevent recurrence (Evidence: Strong) 1.
Regular Follow-Up Post-Excision: Monitor for recurrence every 3-6 months for the first year, then annually (Evidence: Moderate) 1.
Refer to Dermatopathologist or Orthopedic Surgeon for Recurrent or Atypical Cases: For specialized evaluation and management (Evidence: Expert opinion) 1.
Consider Additional Imaging if Recurrence is Suspected: To assess extent and guide further management (Evidence: Moderate) 1.
Evaluate for Underlying Conditions Contributing to Lesion Development: Such as chronic irritation or trauma, especially in special populations (Evidence: Moderate) 1.
Monitor for Malignant Transformation in Cases with Atypical Histological Features: Close surveillance and multidisciplinary approach may be necessary (Evidence: Weak) 1.
Educate Patients on Symptoms of Recurrence: Emphasize the importance of prompt reporting of new symptoms (Evidence: Expert opinion) 1.
Avoid Unnecessary Aggressive Treatments: Ensure accurate diagnosis to prevent overtreatment (Evidence: Expert opinion) 1.References
1 Elsensohn A, Getty S, Shiu J, de Feraudy S. Intradermal Proliferative Fasciitis Occurring With Chondrodermatitis Nodularis Helicis. The American Journal of dermatopathology 2018. link
2 Chiu YJ, Liao WC, Wang TH, Shih YC, Ma H, Lin CH et al.. A retrospective study: Multivariate logistic regression analysis of the outcomes after pressure sores reconstruction with fasciocutaneous, myocutaneous, and perforator flaps. Journal of plastic, reconstructive & aesthetic surgery : JPRAS 2017. link
3 Robinson JK, Hanke CW. Injectable collagen implant: histopathologic identification and longevity of correction. The Journal of dermatologic surgery and oncology 1985. link